- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
DEXA sales pace Hologic revenues
Bone densitometry firm Hologic enjoyed a strong fiscal 1996 thanksto higher sales of its Acclaim series of dual-energy x-ray bonedensitometers. The Waltham, MA, company's acquisition of miniC-arm manufacturer FluoroScan Imaging Systems also contributedto
Bone densitometry firm Hologic enjoyed a strong fiscal 1996 thanksto higher sales of its Acclaim series of dual-energy x-ray bonedensitometers. The Waltham, MA, company's acquisition of miniC-arm manufacturer FluoroScan Imaging Systems also contributedto Hologic's revenue growth.
For the year (end-September), Hologic posted revenues of $91.6million, up 62% compared with sales of $56.5 million in fiscal1995. The company's net income for the year stood at $11.4 million,compared with $3.3 million the year before, when a legal battlewith Lunar squeezed Hologic's profits.
For the fourth quarter, Hologic had revenues of $24.4 million,up 46% compared with sales of $16.7 million in the fourth quarterof 1995. The company's net income was $2.1 million, compared with$988,000 in the same period a year ago.
While the FluoroScan acquisition added over $3 million in salesto Hologic's fourth quarter, most of the company's growth camethrough sales in the bone densitometry segment: Hologic's revenuein the period would have grown 64% without the FluoroScan acquisition.Sales of Acclaim systems reached record levels in the U.S. dueto new drugs for treating osteoporosis, according to Hologic chairmanand CEO David Ellenbogen.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
